Mako Yamamoto

In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration

Keiichiro Suzuki, Yuji Tsunekawa, Reyna Hernández‐Benítez et al. · Nature · 2016 · 1.1K citations · Full text

In Vivo Gene Therapy, Genetics, Molecular Biology +6

In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice

Kristen Browder, Pradeep Reddy, Mako Yamamoto et al. · Nature Aging · 2022 · 217 citations

Developmental Biology, Aging, Longevity +8

Single-dose CRISPR–Cas9 therapy extends lifespan of mice with Hutchinson–Gilford progeria syndrome

Ergin Beyret, Hsin‐Kai Liao, Mako Yamamoto et al. · Nature Medicine · 2019 · 152 citations

Single-dose Crispr–cas9 Therapy, Natural Sciences, Immunology +8

In vivo reprogramming of wound-resident cells generates skin epithelial tissue

Masakazu Kurita, Toshikazu Araoka, Tomoaki Hishida et al. · Nature · 2018 · 140 citations · Full text

Regenerative Medicine, Skin Development, Induced Pluripotent Stem Cell +10

Efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models

Yukihiko Hiroshima, Yong Zhang, Takashi Murakami et al. · Oncotarget · 2014 · 129 citations · Full text